2024
DOI: 10.3389/fonc.2024.1380584
|View full text |Cite
|
Sign up to set email alerts
|

KRAS G12C inhibitor combination therapies: current evidence and challenge

Hirotaka Miyashita,
Shumei Kato,
David S. Hong

Abstract: Although KRAS G12C inhibitors have proven that KRAS is a “druggable” target of cancer, KRAS G12C inhibitor monotherapies have demonstrated limited clinical efficacy due to primary and acquired resistance mechanisms. Multiple combinations of KRAS G12C inhibitors with other targeted therapies, such as RTK, SHP2, and MEK inhibitors, have been investigated in clinical trials to overcome the resistance. They have demonstrated promising efficacy especially by combining KRAS G12C and EGFR inhibitors for KRAS G12C-mut… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2025
2025

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 9 publications
references
References 97 publications
0
0
0
Order By: Relevance